More than 300,000 patients could be forced to find new doctors after Michigan Medicine told Blue Cross Blue Shield of Michigan (BCBSM) it will walk away from the insurer's commercial network on July 1 – an escalation in a contract dispute that has exposed deep fault lines over hospital pricing in the state.
The health system communicated its decision in a March 2 letter to BCBSM during what both sides describe as difficult negotiations.
At the heart of the standoff is Michigan Medicine's push for a 44% increase in reimbursement – a figure Blue Cross Blue Shield has publicly rejected as unsustainable.
Michigan Medicine sees it differently. The health system has previously told Crain's Detroit Business that BCBSM pays 22% less than what all other major commercial insurers pay for the same services, casting its demand not as a premium but a correction.
Andrew Hetzel, BCBSM's vice president for corporate communications, said the health system's decision drags patients into a financial fight. "Causing people to worry about their health care is no way to win an argument over money," Hetzel said, adding that Michigan Medicine already charges the highest prices in the state.
Blue Cross has countered that its offers include annual rate increases above current levels, and pushed back against Michigan Medicine's public claims that the insurer's proposals amount to a 30% payment cut.
Hetzel said the insurer's goal is "to arrive at a reasonable, responsible and affordable contract with Michigan Medicine that maintains access to care for our members."
The stakes are considerable. BCBSM has 4.5 million members statewide, and the 300,000 patients at risk of losing in-network access rely on 16 facilities across southeast Michigan, including University Hospital, C.S. Mott Children's Hospital, Rogel Cancer Center, and Frankel Cardiovascular Center.
Medicare, Medicaid, and west Michigan operations would not be affected.
Both parties enter the standoff under financial pressure, though of very different kinds. BCBSM, a Detroit-based nonprofit mutual, disclosed earlier this year that it paid US$2.6 billion more in medical and pharmacy claims in 2024 than the prior year, pushing total payouts past US$23 billion.
Michigan Medicine, meanwhile, reported an operating income of nearly US$234 million in its most recent fiscal year — a stronger result than expected.
Neither side has indicated a timeline for resuming talks. The July 1 deadline stands.
